Literature DB >> 24557675

Clinical manifestations and outcomes in severe ulcerative colitis.

Xuesong Yang1, Wei Yao, Wenbin Liu, Jun Li, Yumin Lu.   

Abstract

In order to evaluate the clinical manifestations and outcomes of severe ulcerative colitis (UC), we retrospectively reviewed 41 patients with severe UC from 144 consecutively hospitalized UC cases from 1988 to 2004. Data recorded included onset, symptoms, signs, laboratory results, endoscopic, radiologic and pathologic findings, the clinical treatment process and follow-up. Of these severe cases, 92.7% (38/41) had pancolitis. Clinically, 36.9% (15/41) were categorized as first onset type, 36.9% (15/41) were chronic persistent and 26.8% (11/41) were chronic recurrent. Steroids played a main role in the remission of severe UC (61.0%). Thirty-one cases (75.6%) were relieved by drug therapy. Seven cases (17.1%) progressed to the need for operation. An early age of onset, pancolitis, low hemoglobin and serum albumin levels, and the need for intravenous steroids tended to be associated with the need for surgery. In conclusion, most of the severe UC patients respond well to drug therapy, but for individuals who are unresponsive to drug therapy, or for those depending on steroids, after a reasonable duration of treatment, the necessity for surgery should be considered.

Entities:  

Year:  2007        PMID: 24557675     DOI: 10.1007/s11684-007-0036-0

Source DB:  PubMed          Journal:  Front Med China        ISSN: 1673-7342


  12 in total

Review 1.  Drug therapy for ulcerative colitis.

Authors:  Chang-Tai Xu; Shu-Yong Meng; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

Review 2.  How effective are the usual treatments for ulcerative colitis?

Authors:  J R Bebb; B B Scott
Journal:  Aliment Pharmacol Ther       Date:  2004-07-15       Impact factor: 8.171

Review 3.  Review article: the management of mild to severe acute ulcerative colitis.

Authors:  S P L Travis
Journal:  Aliment Pharmacol Ther       Date:  2004-10       Impact factor: 8.171

4.  Severe ulcerative colitis: prospective study of parameters determining outcome.

Authors:  Sanjay Kumar; Uday C Ghoshal; Rakesh Aggarwal; Vivek A Saraswat; Gourdas Choudhuri
Journal:  J Gastroenterol Hepatol       Date:  2004-11       Impact factor: 4.029

5.  [Severe ulcerative colitis].

Authors:  L Aspenvall; E Aadland
Journal:  Tidsskr Nor Laegeforen       Date:  1990-05-10

6.  Cyclosporin for severe ulcerative colitis attacks.

Authors:  Ahmet Danalioglu; Sabahattin Kaymakoglu; Zeynel Mungan; Cetin Karaca; Kadir Demir; Ziyaettin Durakoglu; Fatih Besisik; Gungor Boztas; Yilmaz Cakaloglu; Atilla Okyen
Journal:  Hepatogastroenterology       Date:  2003-12

7.  Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery.

Authors:  G T Ho; C Mowat; C J R Goddard; J M Fennell; N B Shah; R J Prescott; J Satsangi
Journal:  Aliment Pharmacol Ther       Date:  2004-05-15       Impact factor: 8.171

8.  [Surgery in severe ulcerative colitis: our experience].

Authors:  M Ghirardi; F Di Fabio; P P Mariani; R Nascimbeni; B Salerni
Journal:  Ann Ital Chir       Date:  2003 Sep-Oct       Impact factor: 0.766

9.  Standard treatment of ulcerative colitis.

Authors:  Paolo Gionchetti; Fernando Rizzello; Flavio Habal; Claudia Morselli; Cristina Amadini; Rossella Romagnoli; Massimo Campieri
Journal:  Dig Dis       Date:  2003       Impact factor: 2.404

10.  Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment.

Authors:  L Benazzato; R D'Incà; F Grigoletto; E Perissinotto; V Medici; I Angriman; G C Sturniolo
Journal:  Dig Liver Dis       Date:  2004-07       Impact factor: 4.088

View more
  1 in total

1.  Tonifying-Qi-and-Detoxification Decoction attenuated injuries of colon and lung tissues in ulcerative colitis rat model via regulating NF-κB and p38MAPK pathway.

Authors:  Xin Yan; Xue Yu; Chunhua Jiang; Ying Cao; Liang Zhu; Chenguang Du; Yongsen Jia
Journal:  Ann Transl Med       Date:  2022-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.